The important question around this telehealth peptide service is practical: what is actually known, what remains uncertain, and what safeguards a licensed clinician and pharmacy process add before anyone treats it as an option.
A patient I’ll call Renee sat across from me on a telehealth screen last October, crying. She’d been on three SSRIs, tried buspirone, done 18 months of CBT, and still couldn’t get through a Monday morning team meeting without her heart hammering into her throat. Her psychiatrist was supportive but running low on ideas. Her sister had sent her a Reddit thread about Selank. “Is this real, or is it another thing that sounds good on the internet?” she asked.
It’s a fair question. And the honest answer is: it’s somewhere in between.
Selank is a synthetic heptapeptide, developed by the Russian Academy of Medical Sciences as an analog of tuftsin, an endogenous immunomodulatory fragment. It is not FDA-approved. It has been used clinically in Russia for anxiety-spectrum conditions for years. And it is increasingly showing up in US compounding practice for patients like Renee, people who’ve genuinely exhausted conventional options and are looking for something else to try under supervision.
Here’s what I think patients and prescribers should actually know.
The Mechanism Is Interesting. The Evidence Is Thin.
The proposed pharmacology: Selank appears to modulate GABA and serotonin systems, influence enkephalinase activity, and produce anxiolytic effects without the sedation or dependence patterns seen with benzodiazepines. That’s the pitch, and mechanistically, it’s plausible.
The published literature that clinicians most often reference includes Kozlovskaya et al. (2003), who characterized Selank’s anxiolytic effects in animal models; Zozulia et al. (2008), who reported clinical observations in patients with generalized anxiety disorder; and Medvedev et al. (2015), who summarized the neurochemical mechanism work on Selank and related regulatory peptides.
Here’s the catch: nearly all of the clinical data is Russian-language, and much of it predates the kind of randomized controlled trial methodology Western regulatory agencies expect. There are no large, placebo-controlled, Western-standard RCTs in English-language journals. That doesn’t mean the molecule is useless. It means the evidence base is pre-validation, and anyone who tells you otherwise is either uninformed or selling something.
The honest comparison is this: SSRIs and SNRIs have decades of rigorous human trial data for anxiety disorders. Benzodiazepines work fast but carry well-documented tolerance and dependence risk. Selank has mechanistic plausibility and preliminary clinical observations, but nothing that would get it through an FDA advisory committee today. For a patient with treatment-resistant anxiety, the question isn’t “Selank or Zoloft?” It’s “I’ve already tried Zoloft and three other things. Is there enough signal here to justify a supervised trial?”
My own opinion: for patients who’ve been through adequate trials of first-line agents and evidence-based psychotherapy, a short, structured Selank trial with a prescriber who knows what they’re looking at is a reasonable conversation to have. It is not a reasonable first step.
What a Compounded Protocol Actually Looks Like
Selank is compounded as an intranasal spray. Typical dosing in practice: 250 to 500 mcg per nostril, two to three times daily, in courses of two to four weeks.
That phrasing (“courses”) matters. This isn’t something you start and forget about like a statin. A well-designed Selank trial has a few specific features:
An agreed-upon success metric before starting. What are we measuring? GAD-7 scores? Panic frequency? Sleep latency? The patient and prescriber should define this upfront. “I just feel better” is hard to evaluate four weeks later.
Baseline labs where relevant. For Selank, the lab workup is lighter than for, say, growth hormone secretagogues (no IGF-1 panel needed), but a basic metabolic picture and documentation of the patient’s current psychiatric medication list are non-negotiable.
A midpoint check-in. Usually a quick telehealth visit around week two. Tolerability, any new symptoms, preliminary sense of response.
An end-of-trial decision. Continue, adjust, or stop. “Continue” should not be the default. Compounded peptides are not meant for indefinite use without reassessment, and I’d argue this is where a lot of patients and even some clinicians get sloppy.
A labeled product from a licensed 503A pharmacy. Prescription number, lot number, beyond-use date, storage instructions. If your vial doesn’t have those, stop and ask questions.
Side Effects and the “Call Your Prescriber” List
The commonly reported side effects are underwhelming in a reassuring way: mild nasal irritation, occasional headache. Published Russian clinical work has not shown a consistent pattern of dependence or withdrawal, which is part of what makes Selank appealing compared to benzodiazepines for anxious patients.
But “generally well tolerated” is not the same as “nothing can go wrong.” What should trigger an immediate prescriber call: any allergic reaction (swelling, rash, difficulty breathing), persistent worsening of the baseline anxiety complaint, any new psychiatric symptom that wasn’t there before (agitation, mood instability, intrusive thoughts), or any lab change outside the agreed range at reassessment.
The nasal irritation piece is worth mentioning specifically because patients with a history of nasal pathology (chronic sinusitis, prior nasal surgery, deviated septum affecting spray delivery) should discuss this with their prescriber before starting. Route of administration matters.
See also: The Impact of Technology on Mental Health
What It Costs (Because Nobody Talks About This Clearly Enough)
Compounded Selank through a licensed 503A pharmacy typically runs $80 to $220 per month at standard doses. Prescriber visits are separate, usually $100 to $300 for an initial telehealth consultation, with follow-ups in a similar range.
Insurance does not generally cover any of this. Not the medication, not the visits (when billed as peptide consultation rather than standard primary care). This is an out-of-pocket commitment, and patients should factor in the full trial cost before starting: medication, initial visit, midpoint check, end-of-trial reassessment. For a four-week trial, you’re probably looking at $400 to $800 all in. That’s not trivial, and it should be weighed against the strength of the evidence, which (as noted above) is preliminary.
The access pathway in 2026 is mostly telehealth. Intake form, optional labs (some practices require them, some don’t), video visit with the prescriber, e-prescription to a partnered 503A compounding pharmacy, shipped medication, and a follow-up at trial’s end.
Where Selank Fits in a Broader Anxiety Treatment Plan
This is the part I care about most, and the part that gets lost in peptide enthusiasm.
Selank is not a standalone treatment for anxiety. It is, at best, one input into a broader plan where the foundations are already in place: adequate psychotherapy, psychiatric medication management (if indicated), sleep hygiene, exercise, and primary care follow-up. Think of it like adding a specialized supplement to a diet that already includes actual meals. The supplement is pointless if you’re skipping the meals.
For patients with treatment-resistant anxiety specifically, “treatment-resistant” should mean genuinely resistant, not “I tried one SSRI for three weeks and didn’t like how it felt.” Multiple adequate trials of first-line agents, evidence-based psychotherapy (CBT, ACT, or similar), and a psychiatrist or primary care provider who’s been part of the process. If those boxes are checked and the patient is still suffering, a supervised Selank trial is a defensible next step.
For readers who want to see the standard compounded workflow written out (prescriber intake, baseline labs, dose ranges, reassessment timeline), this telehealth peptide service walks through the process used in clinical practice.
The 503A Compounding Framework (Quick Primer)
The regulatory mechanism that makes compounded Selank available in the US is the 503A compounding pathway. A licensed pharmacy prepares a patient-specific medication on a valid prescription from a licensed prescriber. This is distinct from 503B outsourcing facilities, which produce larger non-patient-specific batches under different FDA oversight.
Most peptide compounding for individual patients runs through 503A pharmacies operating under state board of pharmacy oversight and USP 797/800 standards for sterile compounding. A patient should expect a labeled vial with prescription number, lot number, beyond-use date, and storage instructions on every shipment. If any of those are missing, that’s a red flag worth investigating before using the product.
Frequently Asked Questions
Is Selank FDA-approved?
No. Selank is not FDA-approved. It has been used clinically in Russia for anxiety-spectrum conditions. The compounded prescription pathway exists because 503A pharmacies can prepare patient-specific medications on a prescriber’s order, even when no FDA-approved commercial product matches the desired formulation.
How long does a typical Selank trial last before reassessment?
Most clinical compounding protocols run two to four week courses, repeated as clinically indicated. Reassessment pairs symptom tracking (anxiety scales, sleep logs, patient-reported outcomes) with objective measures where relevant.
What does Selank cost in compounded form?
Roughly $80 to $220 per month for the medication at typical compounded doses through a licensed 503A pharmacy. Telehealth prescriber fees are separate, typically $100 to $300 for an initial visit with follow-ups in a similar range.
What are the common side effects of Selank?
Mild nasal irritation and occasional headache are the most commonly reported. Published clinical work has not identified a consistent pattern of dependence or withdrawal. Patients with relevant medical history should review the full side effect profile with their prescribing clinician before starting.
Can Selank be combined with other peptides or medications?
Combination protocols exist but should be designed by the prescribing clinician, not assembled by the patient from internet forums. Interactions with current psychiatric medications (particularly SSRIs being initiated concurrently) need explicit discussion.
Who should not use Selank?
Patients with untreated psychiatric disease, pregnancy, concurrent SSRI initiation, or a history of nasal pathology should not start a trial without specialist evaluation and clear documentation of the risk-benefit analysis. Compounded peptides are not a substitute for evidence-based treatment of active disease.
How is Selank administered?
As a compounded intranasal spray. Typical dosing is 250 to 500 mcg per nostril, two to three times daily. Proper spray technique matters for consistent delivery, and patients should be instructed on this during the prescriber visit.
Not FDA-approved. Compounded peptides are prepared by licensed 503A pharmacies for individual patients based on a prescriber’s clinical judgment. Individual results vary. This content is educational and does not replace evaluation by a qualified clinician.
